




Terbinafine

Revised: October 31, 2018.

CASRN: 91161-71-6



Drug Levels and Effects

Summary of Use during Lactation

Limited information indicates that oral maternal doses of 500 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. Monitor the infant for jaundice or other signs of liver toxicity, especially in younger, exclusively breastfed infants. Some sources recommend avoiding oral terbinafine during nursing.[1]

Topical terbinafine has not been studied during breastfeeding. Because only about 1% is absorbed after topical application, it is considered a low risk to the nursing infant.[1][2] Avoid application to the nipple area and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Only

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

water-miscible cream, gel or liquid products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.[3]

Drug Levels

Maternal Levels. A review article states that 2 women excreted totals of 0.7 and 0.2 mg in their milk after a single oral dose of 500 mg of terbinafine.[4] The details of this study were obtained from the manufacturer (Sandoz). Two healthy women aged 32 and 33 years and weighing 57.9 kg and 53.1 kg, respectively, were not breastfeeding, but had some milk production. They were each given four 125 mg tablets of terbinafine after an 8-hour fast. All milk was collected at 6-hour intervals for 72 hours after the dose. The highest concentrations of terbinafine in milk occurred in the first 6-hour aliquot and were 7.3 and 7.9 mg/L, respectively. In the 6- to 12-hour sample, milk concentrations were 2.0 and 2.4 mg/L. In the 12- to 18-hour sample, milk concentrations were 0.15 and 0.25 mg/L. After 18 hours, terbinafine was undetectable (<150 mcg/L[5]) by HPLC assay in milk. The major metabolite of terbinafine was undetectable (<150 mcg/L[5]) by HPLC assay in all aliquots. The cumulative amounts in milk over the 18 hours after the dose were 0.65 mg and 0.15 mg, respectively (noted above as rounded values). Milk production over this time period was 218 mL and 41 mL, respectively.[6] Using the average milk concentration values over the 24-hour period in the 2 subjects, an exclusively breastfed infant would receive 3.8% of the maternal weight-adjusted dosage of terbinafine.

The package insert in the United States states that milk concentrations of terbinafine are 7-fold maternal plasma concentrations. Communication with the U.S. manufacturer, Novartis, indicates that this value was derived from an animal experiment (species not specified). This value is far higher than that found in humans.[6]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Topical to Toenails) [Ciclopirox](#), [Efinaconazole](#), [Tavaborole](#)

References

1. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II Lactation. *J Am Acad Dermatol.* 2014;70:417.e1-417.e10. PubMed PMID: 24528912.
2. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. *Dermatol Clin.* 2006;24:167-97. PubMed PMID: 16677965.
3. Noti A, Grob K, Biedermann M et al. Exposure of babies to C(15)-C(45) mineral paraffins from human milk and breast salves. *Regul Toxicol Pharmacol.* 2003;38:317-25. PubMed PMID: 14623482.
4. Stephen A, Czok R, Male O. Terbinafine: initial clinical results. In, Fromtling RA, ed. *Recent trends in the discovery, development and evaluation of antifungal agents.* Barcelona: JR Prous Science Publishers, SA. 1987;511-20.
5. Schatz F, Haberl H. Analytical methods for the determination of terbinafine and its metabolites in human plasma, milk and urine. *Arzneimittelforschung.* 1989;39:527-32. PubMed PMID: 2751743.
6. Thieme G, Peuckert U. Report on a pharmacokinetic study of SF 86-327 in healthy females in the ablactation period. Sandoz document number 303-019. 1986.

Substance Identification

Substance Name

Terbinafine

CAS Registry Number

91161-71-6

Drug Class

Breast Feeding

Lactation

Antifungal Agents